AR041947A1 - Uso de acetil-l-carnitina o de una sal farmaceuticamente aceptable de la misma para la preparacion de un medicamento para prevenir y/o tratar las neuropatias perifericas inducidas por la administracion de un agente anticancer que induce neuropatias perifericas - Google Patents

Uso de acetil-l-carnitina o de una sal farmaceuticamente aceptable de la misma para la preparacion de un medicamento para prevenir y/o tratar las neuropatias perifericas inducidas por la administracion de un agente anticancer que induce neuropatias perifericas

Info

Publication number
AR041947A1
AR041947A1 ARP030104151A ARP030104151A AR041947A1 AR 041947 A1 AR041947 A1 AR 041947A1 AR P030104151 A ARP030104151 A AR P030104151A AR P030104151 A ARP030104151 A AR P030104151A AR 041947 A1 AR041947 A1 AR 041947A1
Authority
AR
Argentina
Prior art keywords
peripheral neuropathies
carnitine
acetyl
administration
pharmaceutically acceptable
Prior art date
Application number
ARP030104151A
Other languages
English (en)
Inventor
Claudio Cavazza
Claudio Pisano
Loredana Vesci
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Publication of AR041947A1 publication Critical patent/AR041947A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Uso de acetil L-carnitina o de una sal farmacéuticamente aceptable de la misma para la preparación de un medicamento para prevenir y/o tratar las neuropatías periféricas inducidas por la administración de un agente anticáncer que induce neuropatías periféricas con la condición de que dicho agente anticáncer no sea taxol o cisplatino. En particular, dicho agente anticáncer es seleccionado entre el grupo que consiste en la familia de los compuestos de platino, taxanos, la clase epotilona y las alcaloides de vinca, los inhibidores de la farnesil transferasa, talidomida, 5-fluorouracilo, análogos de criptoficina, inhibidores de proteasoma. Dicho medicamento puede ser administrado de una menra coordinada a un paciente que padece dichas neuropatías periféricas, o que se espera que padezca dichas neuropatías periféricas. Se logran efectos beneficiosos en la calidad de vida del paciente y se obtiene una mejora del índice terapéutico del agente anticáncer.
ARP030104151A 2002-11-13 2003-11-12 Uso de acetil-l-carnitina o de una sal farmaceuticamente aceptable de la misma para la preparacion de un medicamento para prevenir y/o tratar las neuropatias perifericas inducidas por la administracion de un agente anticancer que induce neuropatias perifericas AR041947A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/292,823 US20030199535A1 (en) 1998-07-30 2002-11-13 Method for preventing and/or treating peripheral neuropathies induced by the administration of an anticancer agent

Publications (1)

Publication Number Publication Date
AR041947A1 true AR041947A1 (es) 2005-06-01

Family

ID=32312146

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030104151A AR041947A1 (es) 2002-11-13 2003-11-12 Uso de acetil-l-carnitina o de una sal farmaceuticamente aceptable de la misma para la preparacion de un medicamento para prevenir y/o tratar las neuropatias perifericas inducidas por la administracion de un agente anticancer que induce neuropatias perifericas

Country Status (19)

Country Link
US (2) US20030199535A1 (es)
EP (1) EP1562577B1 (es)
JP (1) JP2006508958A (es)
KR (1) KR20050075012A (es)
CN (1) CN1708297A (es)
AR (1) AR041947A1 (es)
AT (1) ATE526958T1 (es)
AU (2) AU2003283807B2 (es)
BR (1) BR0316131A (es)
CA (1) CA2505937C (es)
CY (1) CY1112399T1 (es)
DK (1) DK1562577T3 (es)
ES (1) ES2374503T3 (es)
MX (1) MXPA05004752A (es)
PL (1) PL379244A1 (es)
PT (1) PT1562577E (es)
SI (1) SI1562577T1 (es)
TW (1) TWI362260B (es)
WO (1) WO2004043454A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003018767A2 (en) * 2001-08-27 2003-03-06 Advanced Cell Technology, Inc. Trans-differentiation and re-differentiation of somatic cells and production of cells for cell therapies
MXPA05002113A (es) 2002-08-23 2005-06-03 Sloan Kettering Inst Cancer Sintesis de epotilonas, intermediarios para ellas, analogos y usos de los mismos.
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
ITMI20070817A1 (it) * 2007-04-19 2008-10-20 Farmacetika Ltd Composizione farmaceutica comprendente l-carnitina ed un agente antagonista dei recettori adenosinici di membrana, loro derivati e/o sali farmaceuticamente accettabili, e uso degli stessi nella preparazione di farmaci con effetto non tossico di inibi
WO2008136374A1 (ja) * 2007-04-26 2008-11-13 Nippon Shinyaku Co., Ltd. 抗癌剤投与に伴う末梢神経障害抑制用医薬組成物
CA2698129A1 (en) * 2007-08-31 2009-03-05 Kyushu University, National University Corporation Prophylactic or alleviating agent for peripheral nerve disorder induced by anti-cancer agent
CA2704128A1 (fr) * 2007-10-30 2009-07-30 Trophos Nouvelle composition pour traiter les effets secondaires des traitements anticancereux
CN102215838B (zh) * 2008-12-01 2014-06-18 希格马托制药工业公司 烷酰基l-肉毒碱联合化学治疗药在治疗赘生物中的应用
CN102060722B (zh) * 2009-05-01 2014-06-11 常州高新技术产业开发区三维工业技术研究所有限公司 一种含砷化合物及其制备方法和用途
ITPZ20130005A1 (it) * 2013-07-05 2015-01-06 Teodosio Antonio Ferrara Metabolismo energetico e omeostasi
US11162129B2 (en) 2016-11-09 2021-11-02 IsoPlexis Corporation Photoprotective mixtures as imaging reagents in sequencing-by-synthesis

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4713370A (en) * 1972-11-06 1987-12-15 Felice Stephen L De Carnitine and its use in reducing cardiac toxicity and as a synergist with cytostats
IL74449A (en) * 1984-03-01 1988-07-31 Us Commerce Tetrahalo-1,2-cyclohexane-diamino platinum complexes and anti-neoplastic compositions comprising them
IT1196564B (it) * 1986-08-04 1988-11-16 Sigma Tau Ind Farmaceuti Impiego di acetil l-carnitina nel trattamento terapeutico delle neuropatie periferiche
CA2338638C (en) * 1998-07-30 2009-03-17 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of l-carnitine and its alkanoyl derivatives in the preparation of medicaments with anticancer activity

Also Published As

Publication number Publication date
KR20050075012A (ko) 2005-07-19
CA2505937A1 (en) 2004-05-27
EP1562577A1 (en) 2005-08-17
WO2004043454A1 (en) 2004-05-27
BR0316131A (pt) 2005-09-27
AU2009201384A1 (en) 2009-05-07
MXPA05004752A (es) 2005-08-02
PL379244A1 (pl) 2006-08-07
CA2505937C (en) 2011-07-26
EP1562577B1 (en) 2011-10-05
ATE526958T1 (de) 2011-10-15
TWI362260B (en) 2012-04-21
AU2003283807B2 (en) 2009-12-03
US20030199535A1 (en) 2003-10-23
JP2006508958A (ja) 2006-03-16
US20060183798A1 (en) 2006-08-17
TW200410683A (en) 2004-07-01
DK1562577T3 (da) 2012-01-23
CN1708297A (zh) 2005-12-14
CY1112399T1 (el) 2015-12-09
AU2003283807A1 (en) 2004-06-03
ES2374503T3 (es) 2012-02-17
SI1562577T1 (sl) 2012-01-31
PT1562577E (pt) 2012-01-12

Similar Documents

Publication Publication Date Title
EP1100589B1 (en) Use of propionyl l-carnitine and acetyl l-carnitine in the preparation of medicaments with anticancer activity
ES2089027T3 (es) Forma de dosificacion transmucosica.
RU2017132877A (ru) Комбинация антагониста pd-1 и эрибулина для лечения рака
AR065579A1 (es) Mejoras en composiciones medicinales o relativas a las mismas
AR090885A1 (es) Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple
CY1112399T1 (el) Ακετυλ-l-καρνιτινη για την προληψη και/ή τη θεραπεια περιφερικων νευροπαθειων που προκαλουνται απο θαλιδομιδη
ATE70439T1 (de) Verwendung von acetyl-l-carnitin zur herstellung eines medikamentes zur therapeutischen behandlung von peripheren neuropathien.
RU2008119454A (ru) Лекарственное средство для защиты моторного нейрона у пациентов с боковым амиотрофическим склерозом
RU2007119545A (ru) Пегилированный липосомальный доксорубицин в комбинации с эктеинасцидином 743 (ecteinescidin 743)
BRPI0411451A (pt) formas de dosagens orais de memantina
US2890984A (en) Pharmaceutical composition containing 2-(1, 2, 3, 4-tetrahydro-1-naphthyl)imidazo-line
AR045289A1 (es) Forma de dosificacion oral de liberacion controlada que comprende 4-(2-di-n-propilaminoetil) - 2(3h)-indolona (ropi-nirol) y uso de dicha forma de dosificacion para la elaboracion de un medicamento
AR030039A1 (es) Composicion farmaceutica que comprende una droga inhibidora selectiva de la ciclooxigenasa-2, su uso en la fabricacion de un medicamento para tratar o prevenir afecciones mediadas por la ciclooxigenasa-2 y metodo para hacer dicho medicamento
KR970061244A (ko) 치매 치료용 약학 조성물
KR890006227A (ko) 페놀-함유 진해성 액체 조성물
KR920702225A (ko) 약학 조성물
JP2006508118A5 (es)
Carney et al. Forty-two months experience of flupenthixol decanoate in the maintenance treatment of schizophrenia
KR890014109A (ko) 의약제
AR052138A1 (es) Composicion farmaceutica de liberacion lenta que comprende (+)-(2s,3s)-2-(3-clorofenil)-3,5,5-trimetil-2- morfolinol y su uso para la elaboracion de un medicamento
CN113456643B (zh) 一种含普那布林的药物组合及其应用
DE60112584D1 (de) Verfahren zur Herstellung einer flüssigen Dosierungseinheit und Kit
KR950702413A (ko) 암치료에 2-(4-(4-클로로페닐)시클로헥실)-3-히드록시-1, 4-나프토퀴논을 사용하는 방법(use of 2-(4-(4-chlorophenyl)cyclohexyl)-3-hydroxy-1,4-naphthoquinone for the treatment of cancer)
RU2013141926A (ru) Терапевтическое применение димирацетама для предотвращения ладонно-подошвенного синдрома, вызываемого сорафенибом
RU2002129356A (ru) Комбинация лекарственных средств для лечения головной боли, содержащая нестероидное противовоспалительное лекарственное средство

Legal Events

Date Code Title Description
FA Abandonment or withdrawal